-

SHAREHOLDER ALERT: Robbins LLP is Investigating Array Technologies, Inc. (ARRY) on Behalf of Shareholders

SAN DIEGO & ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Array Technologies, Inc. (NASDAQ: ARRY) to determine whether certain Array officers and directors violated the Securities Act of 1933 and Securities Exchange Act of 1934, and breached their fiduciary duties to the Company. Array purports to be one of the world's largest manufacturers of ground-mounting systems used in solar energy projects.

If you suffered a loss due to Array Technologies, Inc.'s misconduct, click here.

Array Technologies, Inc. (ARRY) Failed to Disclose Rising Costs Would Have an Adverse Effect on its Business Operations

According to a complaint filed against the Company, Array's Offering Materials stated that one of the Company's strengths related to its management of costs. Specifically, the Offering Materials noted the Company's "[d]emonstrated ability to reduce the cost of our products while increasing profit margins" and that its "[r]igorous supply chain management [was] supported by a sophisticated enterprise resource planning ("ERP") system." With regard to strategy, the IPO Materials explained how the Company leveraged its global supply chain and economies of scale to reduce product cost. However, the Company failed to disclose the then-existing rise of costs related to certain supplies such as steel, as well as the Company's freight costs.

On May 11, 2021, Array reported lower revenues year-over-year and lower margins. These dismal financial results included a 44% decrease in revenue for the prior year period, a 63% decrease in gross profit, a 69% decrease in adjusted EBITDA, and 71% decrease in adjusted income. The Company blamed increased steel and shipping costs, and noted, "continuing increases in prices of steel and freight costs will impact our margins in the second quarter and potentially subsequent quarters if prices do not normalize." On this news, Array's stock price dropped $11.49 per share on May 12, 2021, to close at $13.46 per share.

Array Technologies, Inc. (ARRY) shareholders have legal options. If you would like more information regarding your rights, please contact Lauren Levi at (800) 350-6003 or llevi@robbinsllp.com, or via our Shareholder Information Form.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Array Technologies, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:ARRY

Release Versions
$Cashtags

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the FS KKR Capital Corp. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired FS KKR Capital (NYSE: FSK) securities between May 8, 2024 and February 25, 2026. FS KKR Capital is a private credit firm, also known as Business Development Company, which specializes in making private loans to companies.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Ro...

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...
Back to Newsroom